

PARTNERING WITH JAPANESE PHARMA TO COMBAT NEGLECTED DISEASES

GHIT R&D Forum, Tokyo, Japan

December 8th, 2017

Peter Warner, DPhil, MA.

OUR HISTORY




1994

Bill Gates Sr. starts a small philanthropic foundation at his son's request.




1997

Bill and Melinda read an article about rotavirus and are inspired to act.



2000

The Bill & Melinda Gates Foundation is created, with a focus on health, education, and libraries.



2006

Warren Buffett pledges Berkshire Hathaway stock valued at \$31 billion.



2008

Bill joins Melinda full-time at the foundation.



2011

The foundation moves to its new permanent home in Seattle.



2015

The foundation celebrates its 15-year anniversary.

THE SCOPE OF OUR WORK

We work with partner organizations around the world to reduce inequity

Program
Strategies

28



Value of Grants

\$4.3B



Countries

158



Employees

1,453



Grantees

1,176



No. of Grants

1,574



U.S. States

47



Alumni

1,220



HOW WE DO WHAT WE DO



Grantees and partners are at the center of our work



Together, we take risks, push for new solutions and harness the power of science and technology



This work requires support from governments, the private sector, communities, nonprofits and individuals

COMBAT INFECTIOUS DISEASES THAT PARTICULARLY AFFECT THE POOR




We believe we can save lives by delivering the latest in science and technology to those with the greatest needs.


Select examples of this work:

- Accelerate progress to eradicate malaria
- Reduce HIV infections and extend lives of people with HIV
- Deliver life-saving vaccines where they're needed most
- Work to eradicate polio

HOW WE WORK: CROSS-CUTTING FUNCTIONS



TB DRUG ACCELERATOR – AN EXAMPLE OF DRUG DISCOVERY COLLABORATION



PHARMACEUTICAL COMPANIES:



RESEARCH INSTITUTIONS:



■ BMGF AND GHIT – ACTIVATING THE POWER OF JAPAN'S UNIQUE COMPOUNDS AND EXPERTISE

- Japan has a long and highly successful track record of innovation in drug discovery
- Antibiotic drug development has been a particular strength
- The Global Health Innovative Technology Fund provides a unique mechanism to bring assets from Pharma companies in Japan to bear on Neglected Diseases
- The BMGF thanks all the Japanese funders and participating companies for joining with us in our mission to deliver new drugs and vaccines to combat disease that particular afflict the poor.
- We look forward to working with Japanese partners to deliver new drugs and vaccines that will impact on neglected diseases.